How to Choose Diseases for Newborn Screening by Tandem Mass Spectrometry Under the Nationally Recommended Program in Shenzhen, China Evidence From a Cost-Effectiveness Analysis

Mingren Yu

School of Medicine and Health Management, Tongji Medical College of Huazhong University of Science and Technology

Juan Xu (✉ xujuan@hust.edu.cn)

School of Medicine and Health Management, Tongji Medical College of Huazhong University of Science and Technology

Xiaohong Song

Department of Family Development and Maternal and Child Health, Shenzhen Municipal Health Commission

Jiayue Du

Department of Science and Education, the Fourth Affiliated Hospital of School of Medicine, Zhejiang University

Research Article

Keywords: Newborn screening, tandem mass spectrometry, inborn errors of metabolism, cost-effectiveness

Posted Date: June 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-571454/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Newborn screening (NBS) can prevent inborn errors of metabolism (IEMs), which may cause long-term disability and even death in newborns. However, in China, tandem mass spectrometry (MS/MS) screening has just started. This study is to determine the cost-effectiveness of NBS using MS/MS in Shenzhen under the nationally recommended program, and determine IEMs for detection.

Methods: A Markov model was built to estimate the cost and quality-adjusted life-years (QALYs) of different screening programs. The current screening program and nationally recommended program were compared and we also compared the programs detecting different numbers of IEMs, which are chosen from the national program. A sensitivity analysis and budget impact analysis (BIA) were performed.

Results: The incremental cost-effectiveness ratio (ICER) of detecting all 12 IEMs in the national program is 277,823 RMB per QALY, below three times per capita GDP in Shenzhen. MS/MS screening in Shenzhen can be cost-effective only if at least three diseases (PKU, PCD and MMA) are covered and when the screening program covers five diseases (PKU, PCD, MMA, MSUD, IVA), the ICER closely approaches its critical value. The BIA indicated the implementation cost of the national program to be around 580 million RMB over 10 years and showed no difference in budget between programs detecting different numbers of IEMs.

Conclusions: We conclude that the newborn screening using MS/MS in Shenzhen is cost-effective, and the budget affordable for the Shenzhen government. Two concepts for selecting the IEMs to be detected, which we label the “ICER maximization idea” and the “ICER validation idea” are also presented.

Background

Inborn Errors of Metabolism

Inborn errors of metabolism (IEMs) are a group of diseases caused by abnormal biochemical metabolic indicators which block the metabolic pathways in our bodies [1, 2]. While most published studies have numbered IEMs in the 500-700 range [3-5], a recent article estimates the number to be more than 1015 [6], which suggests a high cumulative incidence of IEMs. There are many discrepancies in the prevalence of IEMs reported in these studies. Donald Waters et al. [7] estimated the global birth prevalence to be 50.9 per 100,000 live births based on a systematic literature review of birth prevalence and case fatality of IEMs globally. Other researches indicate prevalence is between 40 per 100,000 and 125 per 100,000 [8, 9]. In China, although epidemiological statistics are absent at the country level, regional data reveals an incidence of IEMs ranging from 35.3 per 100,000 to 136.4 per 100,000 [10-12]. Notwithstanding the actual incidence, it is now clear that IEMs affect a multitude of newborns and families all over the world.

Most IEMs are curable given early detection, but without prompt recognition can give rise to long-term disability and even death [13]. Since IEMs are ingravescent, and overlap in clinical manifestations, early symptoms may not be apparent or are challenging for differential diagnosis, if any [14]. The development of newborn screening (NBS) is now a critical tool in the prevention of primary diseases. IEMs can be detected via NBS in asymptomatic patients. In other words, medical intervention can be made quickly in the early stage to control disease progression [15]. Thus, morbidity and mortality associated with IEMs can be effectively reduced [16], and life-threatening or long-term sequelae prevented [17].

Newborn Screening

Neonatal screening began in the 1970s when Dr. Robert Guthrie developed the dried blood spot (DBS) analysis to measure metabolites in the diagnosis of phenylalanine (PKU) [18]. From there, NBS gradually evolved from a relatively simple test detecting a single congenital condition to a more comprehensive and complex screening system covering over 50 different diseases [19]. Screening methods advanced with the successive application of Gas chromatography/mass spectrometry (GC/MS), liquid chromatography/mass spectrometry (LC/MS), and tandem mass spectrometry (MS/MS) in NBS. Now, MS/MS is the mainstay of NBS given its high specificity and sensitivity [9, 20]. Different conditions, from the most common disease categories to rarer diseases can be simultaneously detected using filter paper spots or directly, in biological fluids [14, 21]. Following Milliton et al. [22] first putting MS/MS into practice in 1990 to identify metabolic disorders in NBS, its use became widespread across countries [23, 24]. By 2010, the MS/MS newborn screening coverage in the US had reached 100% with 20-40 diseases being detected among different states [25]. Moreover, screening rates in other countries, such as Germany, the UK, Japan, and so on, also reached 90% [26].

The number of IEMs screened varies from country to country. In the US and Canada, NBS covers the largest number, 42 IEMs [27, 28]. By contrast, other countries have set the number within the range of 20-30, for example, Australia (21 IEMs), New Zealand (23), and Japan (24) [29-31], which is similar to that set in some provinces of China, such as Taiwan (24), Zhejiang (28) and Hefei (29) [32-36]. In other provinces of Mainland China, the number of IEMs screened for is very limited, only three in Beijing [37, 38] and four in Shenzhen [38]. Additionally, screening programs in South Korea, Germany, and the UK cover less than 20 IEMs, respectively 18, 16, and 9 [31, 39, 40].

The newborn screening program in China was first launched in the 1980s [41]. Since then, significant success has been achieved, with the screening rate increasing from 2% in 1995 to 97.5% in 2017 [42]. The application of the MS/MS method to newborn screening in China began relatively recently, in 2002 [43]. A study revealed that more than 60 laboratories throughout the country had performed MS/MS analysis, and about 40 newborn screening centers had developed the MS/MS screening by 2016 [44]. In China, an increasing number of NBS have adopted using MS/MS rather than the traditional immunofluorescence (IF), which is still the primary means in Shenzhen. Thus, there is an urgent need for the Shenzhen government to implement MS/MS screening throughout the city, especially in the context of *"Newborn Screening Management Measures"*. In February 2019, the Health Commission of Guangdong province revised its *"Newborn Screening Management Measures"*, highlighting the potential application of advanced technologies, such as MS/MS, to NBS in the province.

Economic evaluation of MS/MS newborn screening

Developments in economic evaluations of MS/MS newborn screening in different countries have aimed to provide scientific and reasoned evidence to support and improve newborn screening programs, including Canada [45], Germany [16, 46], the US [47-50], the UK [51, 52], Thailand [53] and other countries [54, 55]. Most of these analyses focus on cost-effectiveness (cost-utility analysis). A smaller proportion of the articles are cost-benefit analyses [56-58]. The vast majority of published articles, excepting a study from Thailand, clearly demonstrate that MS/MS screening in their specific country setting is likely a cost-effective healthcare intervention. However, for lack of essential data about IEMs, the number of diseases incorporated in these analyses is usually less than 10. Further, the studies' results are not comparable given the varying regions, time

frames, incremental cost-effectiveness ratio (ICER) thresholds, etc. employed in studies. Nevertheless, what cannot be ignored is that economic evaluations prove MS/MS newborn screening to be economically efficient, and offer policymakers unequivocal scientific evidence for the benefits of NBS programs.

In China, to say nothing of Shenzhen province, any economic evaluation of MS/MS neonatal screening is yet to be carried out. In an effort to correct this situation, we have conducted this study to determine the cost-effectiveness of MS/MS screening in the social and economic context of Shenzhen based on the diseases nominated by the national program. In doing so, we take into account the government budget and explore how to select the appropriate number of IEMs for detection.

Methods

Selection of IEMs

To guide applicants preparing the material of registration and application for amino acid, carnitine, and succinylacetone detection reagent (MS/MS), the [Center for Medical Device Evaluation](#) of National Medical Products Administration of China (NMPA) enacted "*Guiding Principles for Amino Acid, Carnitine and Succinylacetone Detection Reagent Registration*" in 2019 [59]. The guideline recommends 12 types of IEMs that are relatively common in China and suitable for screening by MS/MS (Table 1). Compared with the numbers of IEMs detected in other countries, it is a conservative recommendation based on China's actual situation, suiting a referable and applicable pilot program for Shenzhen.

Table 1 IEMs in the nationally recommended program

No.	IEMs
1	Phenylketonuria (PKU)
2	Methylmalonic acidemia (MMA)
3	Primary carnitine deficiency (PCD)
4	Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)
5	Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)
6	Isovaleric acidemia (IVA)
7	Glutaric acidemia type I (GAI)
8	Maple syrup urine disease (MSUD)
9	Citrullinemia type II (CIT-II)
10	Citrullinemia type I (CIT-I)
11	Propionic acidemia (PA)
12	Homocystinuria (HCY)

This study measured the inputs and outputs of MS/MS newborn screening from a social perspective. And then, we estimated both cost and effectiveness to calculate the ICER of expanded screening, with the cost and effectiveness discounted at an annual rate of 3%. For the moment, PKU, CH (congenital hypothyroidism), CAH (congenital adrenal hyperplasia) and G6PD deficiency (Glucose-6-phosphate Dehydrogenase deficiency) are compulsorily detected by IF in Shenzhen. Only PKU is incorporated into the expanded screening. So, we compared the program detecting 12 IEMs by MS/MS with merely detecting PKU by IF.

In order to determine an adequate and reasonable number of IEMs, we compared the results of economic evaluations and budget impact analyses of MS/MS screening programs with different disease combinations. First, we conducted a cost-effectiveness analysis on the program detecting every disease to obtain an ICER ranking of various diseases. Since PKU is already covered in the original NBS program, we needed to concentrate only on the other 11 IEMs. We could then finally determine 11 screening strategies according to the ranking. The first strategy includes PKU and the disease with the smallest ICER, and the second includes PKU and the top two diseases. By parity of reasoning, the 11th strategy is the nationally recommended program covering all 12 diseases.

Model Structure

We developed a decision-tree and Markov model to conduct the cost-effectiveness analysis of expanded newborn screening using the following assumptions:

- A child can have only one kind of disease;
- The progress of IEMs is divided into several independent Markov states (health states) according to the main sequelae. And in each cycle, a child can be in only one of the Markov states.
- The states’ future distribution depends only on current events, and not on those that occurred before.

A half-cycle correction was made to the model. Based on the field investigation, the numbers of people participating in NBS from 2016 to 2018 in Shenzhen were 209,443, 228,206 and 206,670, respectively. Also, there were 194,393 puerperae throughout 2019, so we set the cohort at 200,000 newborns with a cycle-length of one year. The Markov model was terminated at the 82nd cycle since the average life expectancy of Shenzhen residents was 82 years in 2018. States transition of IEMs is shown in Fig. 1, and the Markov model structure in Fig. 2.

Sensitivity and Specificity

The screening methods in Shenzhen include immunofluorescence for the current program while MS/MS only for expanded screening. As is showed in Table 2, the former sensitivity and specificity are 100% and 78.6%, and their counterparts are both 100%.

Table 2 Sensitivity and specificity of screening methods

Parameter		Mean	Reference
Fluorometry	Sensitivity	100.00%	[60]
	Specificity	78.60%	
MS/MS	Sensitivity	100.00%	[61] [21]
	Specificity	100.00%	

Event probabilities

In Shenzhen, only the incidence of PKU can be collected. Therefore, this study referred to the MS/MS screening results in Zhejiang, covering 1,861,262 neonates and Nanjing, covering 850,486 neonates, as shown in Table 3. Because of the large numbers of people covered and the high maturity of widely used MS/MS, the incidence data is referable for Shenzhen.

Table 3 The incidence of IEMs

No.	IEMs	Incidence		Reference
1	PKU	1:14028	0.00007128	Filed investigation
2	MSUD	1:206667	0.00000484	[33]
4	CIT I	1:265700	0.00000376	[33]
5	HCY	1:212622	0.0000047	[11]
6	MMA	1:46500	0.00002151	[34]
7	IVA	1:265900	0.00000376	[34]
8	GA I	1:310200	0.00000322	[34]
9	PA	1:310200	0.00000322	[34]
10	PCD	1:23862	0.00004191	[35] ^l
11	MCAD	1:372252	0.00000269	[35]
12	VLCAD	1:620421	0.000001611	[35]

Data for the age-specific mortality and incidence of sequelae of different IEMs between the screening and non-screening groups remain scarce in China, leaving us no alternative but to refer to studies from other countries. In order to simulate the natural progress of diseases more accurately, the rate of death due to other causes was also added to the model as a parameter. This part of event probabilities is detailed in **Additional file 1**.

Costs

The cost of MS/MS screening includes direct costs and indirect costs from a social perspective. Direct costs include direct medical cost and direct non-medical cost. The former consists of expenditures for screening,

confirmation, treatment (for the disease and its sequela), and follow-up, while the latter consists in family transportation costs and the program cost. Indirect costs are due to the lost productivity of families during the confirmation, treatment, and follow-up stages of NBS. Since detection in newborns occurs within six days in the hospital, families do not need to go to any particular hospital, so transportation and lost productivity costs during the screening stage are not counted.

Cost inputs used in the model are shown in Table 4. The data were derived mainly from the field investigation and estimation based on the *Guidelines for the Treatment of Rare Diseases (2019)* [62], drug prices at online pharmacies, and assumptions of this study. Also, we referred to published literature, government policies, and statistical yearbooks if parameters could not be directly obtained or estimated.

Table 4 Model cost parameters presented in 2018 RMB

Parameters		Mean		Reference
Screening by IF (per newborn)		23		Field investigation
Screening by MS/MS (per newborn)		296		Field investigation
Confirmation by IF (per newborn)		319		Field investigation
Confirmation by MS/MS (per newborn)		296		Field investigation
Treatment for the diseases (per person-year) ^a	Age groups^b	0~5 years	6~82 years	<i>Guidelines for the Treatment of Rare Diseases (2019)</i> [62]
	MSUD	13440.90	6083.00	
	HCY	13772.13	5952.51	
	CIT I-CIT II	48202.46	20833.77	
	IVA	17567.81	13045.01	
	GA I	17567.81	13045.01	
	MMA	19023.76	24692.53	
	PA	17567.81	19839.39	
	MCAD-PCD-VLCAD	15853.26	15853.26	
	PKU	15000.00	15000.00	Field investigation
Treatment for sequelae (per person-year) ^c	DD	3,064		[63]
	ND	53,400		[64]
	MR	12,000		[65]
	RD	70,213		[66]
Follow-up (per person-year)	IF (4 times)	1,276		Field investigation
	MS/MS(4 times)	1,184		Field investigation
Transportation (per year)		435		Field investigation
Lost productivity (per year)		3,060		[67]
Program cost	Sample transportation (per year)	42,000		Field investigation
	Printing (per year)	340,000		
	Cold-chain logistics (per year)	470,000		
	Software development and maintenance, equipment updating, etc. (per year)	370,000		

Utilities (per person-year)	2.52	[68], supposing 200,000 people are screened
Administrative management (per person-year)	1.81	
Depreciation of buildings, equipment, etc.	Sunk costs	

^aThe calculation process of the treatment cost of the diseases is detailed in **Additional file 2**.

^bSchoen et al. [57] divide the cost of treatment into two parts at 5 years of age since, in some cases, additional care is needed for children with IEMs detected after symptoms manifest during their first five years. We also found discrepancies between different ages in the treatment and medication criteria for IEMs when referring to *Guidelines for the Treatment of Rare Diseases (2019)*. Therefore, we did the same work to estimate the treatment cost by dividing patients into two groups at age 5.

^cDD: Development Delay; ND: Neurological Damage; MR: Mental Retardation; RD: Renal Damage.

Effectiveness

Quality-adjusted life-years (QALYs) were estimated through the Markov model, multiplying the length of time in different health states by the utility value for states. We also calculated the ICER between current screening and expanded screening programs. An ICER threshold set at 568.704 RMB, three times per capita GDP in Shenzhen, was used in this study. The utility parameters of health states are listed in Table 5, estimated mainly from data in published articles. We presumed the utility of “alive state” to be 1, which means healthy.

Table 5 Model Utility Parameters

Parameter ^a	Mean (range)	Reference
NS	0.900–0.850-0.950	[48]
DD	0.843–0.792-0.881	[49]
ND	0.840–0.700-0.850	[69]
MR	0.790–0.590-0.840	[69]
RD	0.670–0.580-0.740	[70]
Alive	1	Research assumption

^aDD: Development Delay; ND: Neurological Damage; MR: Mental Retardation; RD: Renal Damage.

Sensitivity analysis

We carried out one-way sensitivity analysis and constructed tornado diagrams to assess the uncertainty in the model and the robustness of the results. One-way sensitivity analysis in this study evaluated the influence of the discount rate in the range 0-10% (base value is 3%), with 1% as an interval of 10 categories. Tornado diagrams include factors like the incidence of IEMs, costs (e.g., the cost of screening, confirmation, transportation, etc.),

and utility of health states. The incidence of IEMs was assumed to vary by 50% from their mean value, and costs were 10%. The value of utility being tested varied based on the upper/lower boundaries illustrated in published articles.

Budget impact analysis

Implementing MS/MS screening, the expansion of diseases screened, and the increase in costs will inevitably place a burden on health expenditure, making it necessary to conduct a budget impact analysis (BIA) of MS/MS screening from the standpoint of Shenzhen’s government.

Health expenditure entailed in the frame of this study included the cost of screening, treatment, and follow-up, as well as the program cost. We assumed that these program costs remain unchanged between the expanded screening and the status quo. What should be noted is that children must receive continuous medical treatment following a positive detection. Because of the increasing numbers of patients year by year, the cost of treatment is necessarily cumulative. The treatment cost of MS/MS screening is mainly that of the IEMs without sequelae, since early detection can sharply reduce the occurrence of sequelae, as indicated in the Markov model. By comparison, the treatment cost of current screening is mainly the treatment cost for the IEMs with sequelae. Due to the high mortality rates of some IEMs, we didn’t calculate the treatment cost of patients with diseases which can cause death within their first two years.

BIA was carried out under the assumption of 200,000 newborns screened annually for ten years (2019-2028), and the cost discounted to 2019 RMB at an annual rate of 3%. Nowadays, in Shenzhen, with relevant policies and regulations released [71] and a national medical insurance system established, the cost of screening and treatment is paid for by families and the government conjointly. The government undertakes 80% of the screening cost and 60% of the treatment cost. How the rate of the medical insurance reimbursement is calculated is shown in **Additional file 3**.

Results

Cost-effectiveness analysis and BIA

Detecting 12 IEMs in the nationally recommended program

Table 6 shows the results of the cost-effectiveness analysis of current screening and expanded screening. The ICER is 277822.83029 RMB per QALY, below the ICER threshold (568704RMB) according to the criteria set by the World Health Organization (WHO).

Table 6 Cost-effectiveness analysis of expanded NBS covering 12 IEMs

Strategy	E ^a	Incr. E ^b	C ^c	Incr. C ^d	Incr. C/Incr. E	C/E
Expanded Screening	74.24727	0.00078	478.43036	217.7561	277822.83029	6.44374
Current Screening	74.24649		260.67426			3.51093

^aE: Effectiveness; ^bIncr. E: Incremental Effectiveness; ^cC: cost; ^dIncr. C: Incremental Cost.

To specify the costs of the MS/MS newborn screening program, the results of BIA are detailed in Table 7.

The total cost of expanded screening is 49.06 million RMB in the first year of MS/MS implementation (the cost has been discounted to 2019), increasing to 68.48 million RMB by 2028 at an average annual growth rate of 3.78%. The total health expenditure for the MS/MS screening program in Shenzhen will reach 583.51 million RMB in the next decade, costing a further 48.88 million RMB annually compared to the current NBS program. The cost of screening accounts for most of the expenditure over the whole decade (95.84%). Meanwhile, the cost of treatment increases as time goes by, accounting for only 0.55% of the total cost (0.27 million RMB) in 2019, rising to 7.07% (4.84 million RMB) by 2028.

Table 7 Budget impact analysis results

Year	MS/MS ^a			IF ^b			Difference	
	Screening cost	Treatment cost	Total sum	Screening cost	Treatment cost	Total sum	Screening cost	Total sum
2019	48.78	0.27	49.06	3.79	0.59	4.39	44.99	44.67
2020	50.24	0.69	50.94	3.90	1.48	5.39	46.34	45.55
2021	51.75	1.11	52.86	4.02	2.28	6.30	47.73	46.56
2022	53.30	1.62	54.92	4.14	3.40	7.54	49.16	47.38
2023	54.90	2.06	56.96	4.27	4.33	8.60	50.64	48.36
2024	56.55	2.57	59.12	4.39	5.30	9.70	52.16	49.42
2025	58.25	3.15	61.40	4.53	6.60	11.12	53.72	50.28
2026	59.99	3.72	63.71	4.66	7.87	12.53	55.33	51.19
2027	61.79	4.27	66.06	4.80	9.00	13.80	56.99	52.26
2028	63.65	4.84	68.48	4.95	10.40	15.34	58.70	53.14
Total sum	559.22	24.29	583.51	43.45	51.25	94.70	515.76	488.81

^aMS/MS = Tandem mass spectrometry; ^bIF = immunofluorescence.

Detecting some types of IEMs selected from national recommendations

The results of the cost-effectiveness analysis of screening a single disease are shown in Table 8. ICERs of all screening programs are higher than the threshold, and diseases are ranked by ICER (from minimum to maximum), i.e., PCD, MMA, MSUD, IVA, PA, MCAD, GA I, CIT I, CIT II, HCY, and VLCAD. The ICER of PCD is the minimum as 1108216.27 RMB per QALY, and the ICER of the VLCAD is maximum as 28203412.22 RMB per QALY.

Table 8 Cost-effectiveness analysis of screening 12 diseases singly, presented in 2018 RMB

Diseases	Screening strategies	C	Incr. C	QALY	Incr. QALY	ICER	Ranking ^a
PKU	MS/MS	410.25539	203.80017	74.25221	0.00000	∞	
	IF	206.45521		74.25221			
MSUD	MS/MS	307.50178	307.31381	74.25582	0.0001	2939541.81613	3
	Non-screening	0.18797		74.25572			
CIT II	MS/MS	307.38049	305.81961	74.25577	0.00002	18133638.14892	8
	Non-screening	1.47585		74.25576			
CIT I	MS/MS	306.95720	305.70929	74.25583	0.00001	22672071.81872	9
	Non-screening	1.17992		74.25582			
HCY	MS/MS	307.00731	304.46279	74.25583	0.00001	26835436.29976	10
	Non-screening	2.54451		74.25582			
MMA	MS/MS	327.54199	309.47322	74.25496	0.00023	1322605.02135	2
	Non-screening	18.06877		74.25473			
IVA	MS/MS	308.20978	305.56324	74.25587	0.00004	7470690.98355	4
	Non-screening	2.64653		74.25583			
GA I	MS/MS	308.42023	304.08437	74.25591	0.00002	18017789.44626	7
	Non-screening	4.33586		74.25589			
PA	MS/MS	308.25104	305.73643	74.25590	0.00004	8728484.19878	5
	Non-screening	2.51460		74.25587			
PCD	MS/MS	331.62502	312.33038	74.25399	0.00028	1108216.26950	1
	Non-screening	19.29465		74.25371			
MCAD	MS/MS	306.96104	305.72261	74.25593	0.00002	16900643.21463	6
	Non-screening	1.23843		74.25592			
VLCAD	MS/MS	306.28250	305.54082	74.25599	0.00001	28203412.21901	11
	Non-screening	0.74168		74.25598			

^aIn the ranking of ICERs, the higher the rank, the bigger the ICER, indicating a less cost-effective screening program.

According to the above ICER rankings of diseases, 11 screening strategies were finally devised. The ICER of each screening program is shown in Fig. 3, below. Only the ICER of the first strategy (PKU and PCD) is higher than the threshold, at 748196 RMB per QALY. All other ICERs are below the threshold. As the number of diseases detected increases, the ICER gradually decreases and finally tends to stabilize.

The results of the BIA of the 11 screening strategies above are shown in Fig. 4. Although the screening program's budget grows with the increasing number of diseases detected, there is no significant difference between single program budgets. The budget for all screening programs holds steady, near 580 million RMB.

Sensitivity analysis

We conducted a one-way sensitivity analysis based on the nationally recommended program of 12 IEMs (Fig. 5 and Fig. 6). We discussed the discount rate and other parameters separately, since the former is remarkably influential. It turns out that the ICER is less than three times per capita GDP when the discount rate is $\leq 7\%$ and, particularly when the discount rate is equivalent to 7%, the ICER is very close to the threshold. Also, the ICER is lower than one times per capita GDP (189,568 RMB) as the discount rate is $\leq 1.5\%$, which means the screening program is very cost-effective.

The top three influential parameters are the incidences of PCD (P_PCD), the incidence of MMA (P_MMA), and the cost of screening by MS/MS (C_MSScr). As we can see, the incidence of diseases accounts for a large proportion of top influential parameters, and the top three are the incidences of PCD, MMA, and MSUD. Apart from disease incidence, the cost of screening by MS/MS (C_MSScr), the utility of the state without sequelae (U_NS) and the cost of confirmation by IF (C_FACom) weigh heavily for the ICER. But, no matter how parameters change within the range, the ICER remains below the threshold at all times, clarifying that the results are robust.

Discussion

This study considered the cost-effectiveness of MS/MS newborn screening in Shenzhen, China. From a social perspective, we confirmed that it is cost-effective to implement the expanded screening, with some preconditions. First, it is not economically efficient to detect only one type of disease. Especially for PKU, the results illustrated IF to be a more cost-effective method currently. The factors contributing to this situation is that detecting a single disease cannot embody the advantages of MS/MS – "one blood sampling for multiple diseases" [72] – but reflects that MS/MS is more expansive than IF. Second, MS/MS screening can be cost-effective only if at least three diseases (PKU, PCD and MMA) are covered. The selection of detected IEMs is connected with the incidence of diseases. The higher the incidence is, the more QALYs can be saved and the more diseases detected, and the smaller ICER of the program will be. Moreover, when the screening program covers five diseases (PKU, PCD, MMA, MSUD, IVA), the ICER closely approaches its critical value (since the ICER of the program covering six diseases accounts for more than 95% of the ICER of five diseases).

The above points can explain why the number of NBS programs varies from region to region, and also reveal two policy ideas for selecting the number of diseases covered. One of the policy ideas, we call "ICER maximization idea". "One blood sampling for multiple diseases" allows an MS/MS screening program to cover more IEMs without additional cost. Therefore, screening more diseases leads to more QALYs saved, making the program more economically efficient. The first policy idea finally can attain a maximal ICER as the decision-maker adds more and more IEMs into the NBS program, which is perhaps the reason for the US and Canada setting their number of IEMs at 42. The ICER maximization policy idea significantly proposes the request to regions in terms of the development of social, economic and medical science. The other policy strategy is the "ICER validation idea". Screening IEMs with high regional incidence allows the ICER to access its critical value closely. Moreover, there exists the inevitable problem of how to treat these hard-to-cure diseases. Although various therapies have so far been developed [73], there are several factors such as the cost of treatment, the complexity and difficulty of treatment, patient compliance, and so on [74, 75], which constitute a huge challenge for medical treatment. Newborns detected positive can only, without appropriate medical treatments being available, cause families serious economic and emotional stress. It is therefore wise to include some IEMs with a high incidence and for which reasonable treatment is available in the screening program. And, in this case, the ICER of the program is already close to the minimum value. We believe that's why some countries, such as the UK, South Korea, and Germany, have limited detectable diseases to less than 20. In brief, for the initial implementation of MS/MS screening in Shenzhen, we would suggest utilizing the "ICER validation idea".

The results of this study are generally robust. One-way sensitivity analysis revealed that caution should be taken when the discount rate surpasses 7%. But, statistics indicate that China's annual inflation rate has remained at around 2% for the past decade (owing to COVID-19, the rate once approached 6%, but remained below 7%) [76]. That is to say, the implementation of MS/MS screening in Shenzhen will be cost-effective for some time to come and likely to be highly cost-effective, since inflation sometimes falls below 1.5%.

The findings of the BIA performed demonstrate that no significant difference exists among different programs in the whole budget. As long as we choose a cost-effective screening program, in every year over the next decade budgets will all reach about 58.00 million RMB. Combining this with the ICER of a program detecting five diseases which reaches the critical value, we can conclude that if the budget of the program covering five diseases is affordable for the Shenzhen administration, it is better to screen for all twelve diseases as per the nationally recommended program. According to the *Guidelines for the Treatment of Rare Diseases(2019)*, there are specific and systematic treatments for these diseases.

Here, we also considered whether the Shenzhen government could bear the budget as proposed, and the answer is yes. According to the *Department Final Report of the Health Commission of Shenzhen in 2018* [77], the budget for public health projects in NBS (including screening for hearing, for IEMs, and for trisomies 21, 18, and 13) was 289.21 million RMB at the beginning of 2018. However, the final expenditure was 123.73 million RMB, accounting for 42.7% of the budget. This indicates the sufficiency of Shenzhen government funds to finance an expanded program. Moreover, data from *Health Statistics Summary of Shenzhen in 2019* [78] show that annual government expenditure on medical treatments and health services increased from 8.332 billion RMB in 2014 to 19.09 billion RMB in 2018, with an annual growth rate of 23.03%, which is much larger than the annual growth rate of the cost of MS/MS newborn screening program.

Another of our team's studies[79], to investigate patients' willingness to pay (WTP) for the MS/MS screening, revealed the average WTP value was 242 RMB, and that 68.71% (404/588) of families were willing to pay more than 200 RMB. So, the payment policy is truly flexible when the WTP value is compared with 20% of the screening cost (average 60.98RMB-79.57RMB per year) that a family should currently be able to afford. And if policymakers are concerned about the risks of health expenditure, it is opportune to increase the proportion of out-of-pocket payment to relieve the high-cost burdens of government. Such a policy change would, however, need to be properly considered since the aim of "*gradually providing the NBS program free of charge*" was proposed in a recent provincial policy. Briefly, the series of data presented above makes the claim that the MS/MS newborn screening program is affordable for the Shenzhen government.

Due to the lack of epidemiological investigation in China and Shenzhen, the integral local database of IEMs is still extraordinarily wanting. So, in order to shorten the odyssey, key recommendations are for research that outlines top priorities to enhance epidemiological studies of IEMs, and advance the establishment of the IEMs database in China. Only in this way can we proceed with a cost-effectiveness analysis suiting China's circumstances and provide further empirical evidence for the NBS program.

Conclusion

We have attempted to put forward policy suggestions for choosing diseases for MS/MS screening in Shenzhen, conducting a cost-effectiveness analysis based on the 12 IEMs recommended by NMPA. This study has confirmed that MS/MS screening covering at least three diseases is cost-effective. The Shenzhen government is entirely able to undertake the budget for the screening program. This study also discussed two policy concepts for selecting IEMs for detection. One, the "ICER maximization idea", represents the strategy of choosing to maximize the ICER of the expanded program. The other, the "ICER validation idea", which considers the curability and affordability of the disease as the basis of healthcare decisions, and achieves a cost-effective ICER for the screening program.

Abbreviations

BIA: Budget impact analysis; CAH: Congenital adrenal hyperplasia; CH: Congenital hypothyroidism; CIT-I: Citrullinemia type I; CIT-II: Citrullinemia type II; DBS: Dried blood spot; DD: Development Delay; GAI: Glutaric acidemia type I; G6PD deficiency: Glucose-6-phosphate Dehydrogenase deficiency; GC/MS: Gas chromatography/mass spectrometry; HCY: Homocystinuria; ICER: Incremental cost-effectiveness ratio; IEMs: Inborn errors of metabolism; IF: Immunofluorescence; IVA: Isovaleric acidemia; LC/MS: Liquid chromatography/mass spectrometry; MCAD: Medium-chain acyl-CoA dehydrogenase deficiency; MMA: Methylmalonic acidemia; MR: Mental Retardation; MS/MS: Tandem mass spectrometry; MSUD: Maple syrup urine disease; NBS: Newborn screening; ND: Neurological Damage; NMPA: National Medical Products Administration of China; PA: Propionic acidemia; PCD: Primary carnitine deficiency; PKU: Phenylalanine; QALYs: Quality-adjusted life-years; RD: Renal Damage; VLCAD: Very long-chain acyl-CoA dehydrogenase deficiency; WHO: World Health Organization; WTP: Willingness to pay.

Declarations

Ethical approval and consent to participate

Conduction of this audit program had been performed in accordance with **the Declaration of Helsinki** and reported to the Tongji Medical School Ethics Commission. The Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (IORG No: IORG0003571) give a final APPROVAL on 24/07/2019 for the study. Written informed consent was obtained from all subjects before the start of the study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interest

The authors declare that they have no competing interests.

Funding

This work was supported by Shenzhen Health Development Research Center⁰²³¹⁰⁵¹⁶⁰⁰⁴⁸. No additional funding was obtained.

Authors' contribution

JX, JD and MY participated in the study design. JX and MY participated in theoretical parts of manuscript and drafted the manuscript. XS is responsible for collecting data. MY and JD is responsible for data management and statistical analysis. JX, MY, XS and JD revised the manuscript. All authors took part the interpretation of findings and have approved the revised manuscript.

Acknowledgements

Not applicable.

Author details

¹ School of Medicine and Health Management, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

² Hubei Provincial Research Center for Health Technology Assessment, Wuhan, China

³ Department of Family Development and Maternal and Child Health, Shenzhen Municipal Health Commission, Shenzhen, China

⁴ Department of Science and Education, the Fourth Affiliated Hospital of School of Medicine, Zhejiang University, Zhejiang, China

References

1. Pollitt, R.J., et al., *Neonatal screening for inborn errors of metabolism: cost, yield and outcome*. Health Technol Assess, 1997. **1**(7): p. i-iv, 1-202.
2. Seymour, C.A., et al., *Newborn screening for inborn errors of metabolism: a systematic review*. Health Technol Assess, 1997. **1**(11): p. i-iv, 1-95.
3. Alfadhel, M., et al., *Thirteen year retrospective review of the spectrum of inborn errors of metabolism presenting in a tertiary center in Saudi Arabia*. Orphanet J Rare Dis, 2016. **11**(1): p. 126.
4. Illsinger, S. and A.M. Das, *Impact of selected inborn errors of metabolism on prenatal and neonatal development*. IUBMB Life, 2010. **62**(6): p. 403-13.
5. Tebani, A., et al., *Clinical Metabolomics: The New Metabolic Window for Inborn Errors of Metabolism Investigations in the Post-Genomic Era*. Int J Mol Sci, 2016. **17**(7).
6. Ferreira, C.R., et al., *A proposed nosology of inborn errors of metabolism*. Genet Med, 2019. **21**(1): p. 102-106.
7. Waters, D., et al., *Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence*. J Glob Health, 2018. **8**(2): p. 021102.
8. Ghosh, A., et al., *Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing*. Arch Dis Child, 2017. **102**(11): p. 1019-1029.
9. Mussap, M., M. Zaffanello, and V. Fanos, *Metabolomics: a challenge for detecting and monitoring inborn errors of metabolism*. Ann Transl Med, 2018. **6**(17): p. 338.
10. Li, Q., et al., *1999–2018 Nian Zhe Jiang Sheng Xin Sheng Er Yi Chuan Dai Xie Bing Shai Cha Qing Kuang Fen Xi [Analysis on neonatal screening for inherited metabolic diseases in Zhejiang Province from 1999 to 2018]*. Preventive Medicine, 2019. **31**(11): p. 1081-1085.
11. Ma, S., et al., *He Nan Sheng 2013-2019 Nian Xin Sheng Er Yi Chuan Dai Xie Bing Shai Cha Hui Gu Xing Fen Xi [Retrospective analysis on screening of neonates inherited metabolic diseases from 2013 to 2019 in Henan province]*. Laboratory Medicine and Clinic, 2020. **17**(14): p. 1965-1968.
12. Sun, Y., et al., *Nan Jing Di Qu 175 767 Li Chuan Lian Zhi Pu Ji Shu Xin Sheng Er Shai Cha Jie Guo Fen Xi [Newborn screening by tandem mass spectrometry in Nanjing: a retrospective analysis of 175 767 cases]*. Chinese Journal of Perinatal Medicine, 2020(04): p. 224-225-226-227-228-229-230-231.
13. Wilcken, B., et al., *Screening newborns for inborn errors of metabolism by tandem mass spectrometry*. N Engl J Med, 2003. **348**(23): p. 2304-12.
14. Ismail, I.T., M.R. Showalter, and O. Fiehn, *Inborn Errors of Metabolism in the Era of Untargeted Metabolomics and Lipidomics*. Metabolites, 2019. **9**(10).
15. Vernon, H.J., *Inborn Errors of Metabolism: Advances in Diagnosis and Therapy*. JAMA Pediatr, 2015. **169**(8): p. 778-82.
16. Tran, K., et al., *Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry*. Clin Biochem, 2007. **40**(3-4): p. 235-41.
17. Almannai, M., R. Marom, and V.R. Sutton, *Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing*. Curr Opin Pediatr, 2016. **28**(6): p. 694-699.
18. Guthrie, R. and A. Susi, *A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS*. Pediatrics, 1963. **32**: p. 338-43.

19. Therrell, B.L., et al., *Current status of newborn screening worldwide: 2015*. Semin Perinatol, 2015. **39**(3): p. 171-87.
20. Annesley, T., et al., *A Spectrum of Views on Clinical Mass Spectrometry*. Clin Chem, 2016. **62**(1): p. 30-6.
21. Pandor, A., et al., *Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review*. Health Technol Assess, 2004. **8**(12): p. iii, 1-121.
22. Millington, D.S., et al., *Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism*. J Inherit Metab Dis, 1990. **13**(3): p. 321-4.
23. Kuehn, B.M., *After 50 years, newborn screening continues to yield public health gains*. Jama, 2013. **309**(12): p. 1215-7.
24. Mechtler, T.P., et al., *Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria*. Lancet, 2012. **379**(9813): p. 335-41.
25. Lehotay, D.C., et al., *LC-MS/MS progress in newborn screening*. Clin Biochem, 2011. **44**(1): p. 21-31.
26. Wang, X., *Jiang Xi Sheng Xin Sheng Er Yi Chuan Dai Xie Bing Shai Cha 20 Nian Hui Gu Yu Zhan Wang [The retrospect and prospect of newborn screening for inherited metabolic disease in Jiangxi Province over two decades]*. 2017, Nan chang University.
27. Health Resources & Services Administration. *Recommended Uniform Screening Panel*. 2020 [cited 2021; Available from: <https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html>].
28. Canadian Organization for Rare Disorders. *Newborn Screening in Canada Status Report*. 2015 [cited 2021; Available from: <https://www.raredisorders.ca/content/uploads/Canada-NBS-status-updated-Sept.-3-2015.pdf>].
29. Human Genetics Society of Australasia. *Recommendations for Screening for Specific Disorders*. 2019 [cited 2021; Available from: <https://www.hgsa.org.au/resources/hgsa-policies-and-position-statements>].
30. National Screening Unit of NewZealand. *Newborn Metabolic Screening Programme - heel prick test - Frequently asked questions : What are babies screened for?* 2014 [cited 2021; Available from: <https://www.nsu.govt.nz/pregnancy-newborn-screening/newborn-metabolic-screening-programme-heel-prick-test/frequently-asked>].
31. Shibata, N., et al., *Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries: Selective screening vs. expanded newborn screening*. Mol Genet Metab Rep, 2018. **16**: p. 5-10.
32. Niu, D.M., et al., *Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan*. J Inherit Metab Dis, 2010. **33**(Suppl 2): p. S295-305.
33. Huang, X., et al., *Zhe Jiang Sheng Xin Sheng Er An Ji Suan Dai Xie Ji Bing Shai Cha Ji Sui Fang Fen Xi [Screening for amino acid metabolic disorders of newborns in Zhejiang province: prevalence, outcome, and follow-up]*. Journal of Zhejiang University (Medical Sciences), 2017. **46**(03): p. 233-239.
34. Hong, F., et al., *Zhe Jiang Sheng Xin Sheng Er You Ji Suan Niao Zheng Shai Cha Ji Sui Fang Fen Xi [Screening for newborn organic aciduria in Zhejiang province: prevalence, outcome, and follow-up]*. Journal of Zhejiang University (Medical Sciences), 2017. **46**(03): p. 240-247.
35. Zheng, J., et al., *Zhe Jiang Sheng Xin Sheng Er Zhi Fang Suan Yang Hua Dai Xie Ji Bing Shai Cha Ji Sui Fang Fen Xi [Screening for fatty acid oxidation disorders of newborns in Zhejiang*

- province:prevalence,outcome and follow-up]. *Journal of Zhejiang University(Medical Sciences)*, 2017. **46**(03): p. 248-255.
36. Hefei Municipal Health Commission. [*Hefei Newborn Screening Program Implementation Plan*]. 2020 [cited 2021; Available from: <http://zwgk.hefei.gov.cn/public/17771/105835811.html>].
 37. Beijing Municipal Health Commission. [*Beijing newborn screening Management Measures*] 2020 [cited 2021; Available from: http://wjw.beijing.gov.cn/zwgk_20040/zxgk/202006/t20200619_1928560.html].
 38. Shenzhen Municipal Health Commission. [*Newborn screening for inborn errors of metabolism*]. 2019 [cited 2021; Available from: http://wjw.sz.gov.cn/ztzl/jksc/dfggwsfwxm/content/post_3122209.html].
 39. Gemeinsamer Bundesausschuss. *Richtlinie zur Früherkennung von Krankheiten bei Kindern in der Version vom 14.05.2020*. 2020 [cited 2021; Available from: <https://www.g-ba.de/sys/suche/?suchbegriff=Neugeborenen-Screening&kategorie=richtlinien&sortierung=inkrafttretendatum>].
 40. National Institute for Health Research. *EXPANDED NEWBORN SCREENING*. 2014 [cited 2021; Available from: <http://www.expandedscreening.org/site/home/start.asp>].
 41. Chen, R., et al., *Xian tian xing jia zhuang xian ji neng di xia de xin sheng er shai cha [NEONATAL SCREENING FOR CONGENITAL HYPOTHYROIDISM]*. *Chinese Journal of Endocrinology and Metabolism*, 1985(02): p. 28-30+64.
 42. National Health Commission of the People's Republic of China. [*Report on the Development of Maternal and Child Health in China (2019)*]. 2019 [cited 2021; Available from: <http://www.nhc.gov.cn/fys/s7901/201905/bbd8e2134a7e47958c5c9ef032e1dfa2.shtml>].
 43. Gu, X., et al., *Chuan Lian Zhi Pu Ji Shu Zai Yi Chuan Xing Dai Xie Bing Gao Wei Er Tong Shai Cha Zhong De Chu Bu Ying Yong [A pilot study of selective screening for high risk children with inborn error of metabolism using tandem mass spectrometry in China]*. *Chinese Journal of Pediatrics*, 2004(06): p. 5-8+85.
 44. Ye, J., *Xin Sheng Er Yi Chuan Dai Xie Bing Shai Cha Fa Zhan Ji Zhen Zhi Gui Fan [Development of newborn screening and diagnosis for inborn errors of metabolism]*. *Chinese Journal of Family Planning & Gynecotokology*, 2016. **8**(01): p. 6-13.
 45. Cipriano, L.E., C.A. Rugar, and G.S. Zaric, *The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model*. *Value Health*, 2007. **10**(2): p. 83-97.
 46. Pfeil, J., et al., *Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis*. *Orphanet J Rare Dis*, 2013. **8**: p. 167.
 47. Carroll, A.E. and S.M. Downs, *Comprehensive cost-utility analysis of newborn screening strategies*. *Pediatrics*, 2006. **117**(5 Pt 2): p. S287-95.
 48. Venditti, L.N., et al., *Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis*. *Pediatrics*, 2003. **112**(5): p. 1005-15.
 49. Tiwana, S.K., K.L. Rascati, and H. Park, *Cost-effectiveness of expanded newborn screening in Texas*. *Value Health*, 2012. **15**(5): p. 613-21.
 50. Feuchtbaum, L. and G. Cunningham, *Economic evaluation of tandem mass spectrometry screening in California*. *Pediatrics*, 2006. **117**(5 Pt 2): p. S280-6.
 51. Bessey, A., et al., *The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism*. *Int J Neonatal Screen*, 2020. **6**(4).

52. Insinga, R.P., R.H. Laessig, and G.L. Hoffman, *Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel*. J Pediatr, 2002. **141**(4): p. 524-31.
53. Thiboonboon, K., et al., *An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand*. PLoS One, 2015. **10**(8): p. e0134782.
54. Hamers, F.F. and C. Rumeau-Pichon, *Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France*. BMC Pediatr, 2012. **12**: p. 60.
55. Autti-Rämö, I., et al., *Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland*. Acta Paediatr, 2005. **94**(8): p. 1126-36.
56. Norman, R., et al., *Economic evaluation of tandem mass spectrometry newborn screening in Australia*. Pediatrics, 2009. **123**(2): p. 451-7.
57. Schoen, E.J., et al., *Cost-benefit analysis of universal tandem mass spectrometry for newborn screening*. Pediatrics, 2002. **110**(4): p. 781-6.
58. Khneisser, I., et al., *Cost-benefit analysis: newborn screening for inborn errors of metabolism in Lebanon*. J Med Screen, 2015. **22**(4): p. 182-6.
59. National Medical Products Administration. *[Guiding Principles for Amino Acid, Carnitine and Succinylacetone Detection Reagent Registration]*. 2019 [cited 2021; Available from: <https://www.nmpa.gov.cn/ylqx/ylqxggtg/ylqxzhdyz/20191115172001960.html>].
60. Liu, w., et al., *Chuan Lian Zhi Pu Fa He Ying Guang Fen Xi Fa Shai Cha Ben Bing Tong Niao Zheng De Dui Bi Fen Xi [Comparative analysis of screening for phenylketonuria by tandem mass spectrometry and fluorescence analysis]*. Maternal and Child Health Care of China, 2018. **33**(24): p. 6020-6022.
61. Huang, X., et al., *Chuan Lian Zhi Pu Ji Shu Dui Xin Sheng Er Yi Chuan Dai Xie Bing De Shai Cha Ji Sui Fang Yan Jiu [Screening for neonatal inborn errors of metabolism by electrospray ionization-tandem mass spectrometry and follow-up]*. Chinese Journal of Pediatrics, 2011. **49**(10): p. 765-770.
62. National Health Commission of the People's Republic of China. *[Guidelines for the Treatment of Rare Diseases (2019)]*. 2019 [cited 2021; Available from: <http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml>].
63. Zhang, F., *Bu Tong Gong Can Mo Shi Xue Sheng Can De Ying Yang Xue He Jing Ji Xue Ping Jia [The nutrition and economic evaluation of school meal with different catering modes]*. 2015, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION.
64. Cui, W., *He Bei Sheng Nao Tan Huan Er Sheng Cun Zhi Liang Zhuang Kuang Diao Cha Yu Jing Ji Fu Dan Ping Jia [Evaluation of Hebei Province to Investigate the Quality of Life and Economic Burden in Children with Cerebral Palsy]*. 2014, Jilin University.
65. Shenzhen Disabled Persons Federation. *[Administrative Measures on Rehabilitation and Assistance Services for Disabled Children in Shenzhen]*. 2018 [cited 2021; Available from: http://www.cjr.org.cn/info/laws/201805/t20180528_19086624.htm].
66. Li, X., *Man Xing Shen Bing Zhi Liao De Wei Sheng Jing Ji Xue Ping Jia [Health Economic Evaluation For Chronic Kidney Disease Treatment]*. 2016, Huazhong University of Science and Technology
67. Shenzhen Bureau of Statistics. *[Shenzhen Statistical Yearbook 2019]*. 2020 [cited 2021; Available from: http://tjj.sz.gov.cn/zwgk/zfxxgkml/tjsj/tjnj/content/post_7971762.html].

68. Shi, J., *Wo Guo Nong Cun Di Qu Zi Gong Jing Ai Shai Cha Fang An De Wei Sheng Jing Ji Xue Ping Jia Yan Jiu* [Cost-effectiveness on Various Modalities of Cervical Cancer Screening in Rural China]. 2009, Peking Union Medical College.
69. Carroll, A.E. and S.M. Downs, *Improving decision analyses: parent preferences (utility values) for pediatric health outcomes*. J Pediatr, 2009. **155**(1): p. 21-5, 25.e1-5.
70. Dionisi-Vici, C., et al., 'Classical' organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inher Metab Dis, 2006. **29**(2-3): p. 383-9.
71. Shenzhen Municipal Health Commission. [Financial subsidies for neonatal inborn errors of metabolism screening costs]. 2016 [cited 2021; Available from: http://wjw.sz.gov.cn/xxgk/tzgg/content/post_3159718.html].
72. Ombrone, D., et al., *Expanded newborn screening by mass spectrometry: New tests, future perspectives*. Mass Spectrom Rev, 2016. **35**(1): p. 71-84.
73. Gambello, M.J. and H. Li, *Current strategies for the treatment of inborn errors of metabolism*. J Genet Genomics, 2018. **45**(2): p. 61-70.
74. Evaluate. *EvaluatePharma Orphan Drug Report 2019*. 2019 [cited 2021; Available from: <https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-orphan-drug-report-2019>].
75. Boyer, S.W., L.J. Barclay, and L.C. Burrage, *Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management*. Nutr Clin Pract, 2015. **30**(4): p. 502-10.
76. TRADING ECONOMICS. [China's inflation rate]. 2021 [cited 2021; Available from: <https://zh.tradingeconomics.com/china/inflation-cpi>].
77. Shenzhen Municipal Health Commission. [Department Final Report of the Health Commission of Shenzhen in 2018]. 2019 [cited 2021; Available from: <http://wjw.sz.gov.cn/attachment/0/600/600932/3133572.pdf>].
78. Shenzhen Municipal Health Commission. [Health Statistics Summary of Shenzhen in 2019]. 2020 [cited 2021; Available from: http://wjw.sz.gov.cn/xxgk/tjsj/zxtjxx/content/post_7786068.html].
79. Du, J., et al., *Yun Chan Fu Dui Xin Sheng Er Yi Chuan Dai Xie Bing Chuan Lian Zhi Pu Shai Cha Ren Zhi Ji Zhi Fu Yi Yuan Fen Xi* [Analysis on cognition and willingness to pay for tandem mass spectrometry screening of neonatal genetic metabolic diseases among pregnant women]. Maternal and Child Health Care of China, 2020. **35**(08): p. 1503-1507.

Figures

Figure 1

States transition of IEMsa a(i) CIT-I-CIT-II-HCY: Mental Retardation [49]; (ii) PKU-GA-I: Neurological Damage [53]; (iii) MCAD-PCD and VLCAD: Development Delay [47]; (iv) IVA-MMA and PA: Neurological Damage and Renal Damage [49]; (v) MSUD: Neurological Damage and Development Delay [49].

Figure 2

Markov model structurea Comparing the expanded screening with the current screening. The expanded program detects 12 IEMs by MS/MS and the current program merely detects PKU by IF. The square represents a decision node, circles chance nodes, and triangles terminal nodes.

Figure 3

ICER of 11 screening strategiesa The line L1 in the figure illustrates the ICER of 11 screening strategies. X-axis represents the screening strategy, y-axis represents the ICER of different screening strategies and the diseases detected in strategies are showed on the right. The first strategy covers PKU and PCD, the second covers PKU,

PCD and MMA. By parity of reasoning, the 11th strategy is the nationally recommended program covering all 12 diseases. Different coloured columns are used to distinguish different strategies.

Figure 4

Budget impact analysis of 11 different screening programsa aColumns represent the whole budget of 11 screening strategies in the decade (2019-2028). Different coloured sections in one column demonstrates the budget of every year.

Figure 5

One-way sensitivity analysis of discount rate in expanded screening

Figure 6

Tornado analysis of newborn screening parametersa aThe parameters are sorted on the right according to their effect on incremental cost effectiveness ratio. The most influential parameter is on the top. EV: Expected value.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.Theagespecificmortalityandtheincidenceofsequelae.docx](#)
- [Additionalfile2.HowtocalculatethetreatmentcostofIEMs.docx](#)
- [Additionalfile3.ActualrateofthemedicalinsurancereimbursementinChina.docx](#)